Singapore keeps monetary settings unchanged as trade tensions ease
The Monetary Authority of Singapore said it will maintain the prevailing rate of appreciation of its exchange rate-based policy band.
The width and the level at which the band is centred were unchanged.
"The risk of a sharp step-down in global growth in the near-term has receded along with the general de-escalation in trade tensions as well as more benign financial conditions since April," the MAS said in a statement. It added it was in an appropriate position to respond to risks after two previous easings.
OCBC economist Selena Ling said the MAS was keeping its ammunition dry and waiting to see the outcome of reciprocal tariffs given the two-way risks for inflation.
"Tariff impact on Chinese exports to rest of the world may be disinflationary, but geopolitics and supply chain recalibrations may be inflationary, so the net impact still has to be assessed," said Ling.
Half of the 12 analysts polled by Reuters ahead of the review expected the MAS to keep policy settings unchanged while the other half forecast an easing of policy.
The MAS eased monetary policy in January and April this year on growth concerns due to U.S. tariffs after holding settings since a tightening in October 2022.
The economy, however, is posting better-than-expected results as exporters rushed out goods to beat the imposition of U.S. tariffs. Singapore avoided a technical recession after the economy grew 1.4% quarter-on-quarter in the second quarter, according to preliminary government data.
Authorities in Singapore have warned that growth is likely to slow in the second half of 2025 as the export and production frontloading tapers off.
"Prospects for the Singapore economy remain subject to significant uncertainty, especially in 2026," the MAS said on Wednesday.
In April, the government reduced its GDP forecast to 0.0% to 2.0% from 1.0% to 3.0%.
Core inflation in the city-state fell to 0.6% year-on-year in June from a peak of 5.5% in early 2023.
Instead of using interest rates, Singapore manages monetary policy by letting the local dollar rise or fall against the currencies of its main trading partners within an undisclosed trading band, known as the Singapore dollar nominal effective exchange rate, or S$NEER.
It adjusts policy via three levers: the slope, mid-point and width of the policy band.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
26 minutes ago
- Reuters
Trump says US will charge tariff of about 100% on semiconductor imports
WASHINGTON, Aug 6 (Reuters) - The United States will impose a tariff of about 100% on semiconductor chips imported into the country, President Donald Trump said on Wednesday. Trump told reporters in the Oval Office that the new tariff rate would apply to "all chips and semiconductors coming into the United States," but would not apply to companies that had made a commitment to manufacture in the United States. "So 100% tariff on all chips and semiconductors coming into the United States. But if you've made a commitment to build (in the U.S.), or if you're in the process of building (in the U.S.), as many are, there is no tariff," Trump said.
Reuters
2 hours ago
- Reuters
European shares end flat as healthcare stocks weigh after Trump's tariff threat
Aug 6 (Reuters) - European shares closed flat on Wednesday, surrendering early session gains, as healthcare stocks felt the pinch from U.S. President Donald Trump's latest threat to impose higher tariffs on pharmaceutical imports. The pan-European STOXX 600 (.STOXX), opens new tab index closed 0.06% lower, breaking its two-day winning streak despite starting the session on a positive note. Healthcare stocks bore the brunt of the selling pressure. The sector index (.SXDP), opens new tab plunged 2.8% to its lowest level in more than three months after Trump unveiled a graduated tariff plan targeting pharmaceutical imports that could see levies on the sector jump up to 250% within 18 months. "This is where it's important to be specific about tariffs because certain stocks and sectors will be impacted differently across regions," said Steve Sosnick, chief market analyst at Interactive Brokers. "In Europe and Asia, investors are considering tariff impacts more carefully since exporters bear much of the brunt directly." The sector was also singed as Novo Nordisk ( opens new tab warned it expects continued competition from copycat versions of its Wegovy obesity drug this year, a message that sent shares of the Danish drug maker down 5.4%. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since then. Meanwhile, Swiss President Karin Keller-Sutter met with U.S. Secretary of State Marco Rubio to discuss potential trade solutions after Trump announced a 39% tariff on Swiss goods. The talks focused on increasing Swiss purchases of U.S. energy and defence products to avert the steep tariff, which threatens significant damage to Switzerland's export-driven economy. Switzerland's benchmark SMI index (.SSMI), opens new tab fell 0.9%, weighed down by drugmakers Novartis (NOVN.S), opens new tab and Roche (ROG.S), opens new tab which lost 3.3% and 2.6%, respectively. Bayer ( opens new tab shares tumbled 9.9% on investor concerns that the German pharmaceutical firm's earnings were inflated by soccer player transfer fees rather than supported by its core healthcare and agriculture businesses. On the data front, Euro zone retail sales grew quicker than thought in June, reinforcing views that the 27-nation bloc remains resilient to trade uncertainty. Among others, Beiersdorf ( opens new tab fell 8.4% and was among top decliners after the German consumer goods maker cut its annual organic sales growth outlook. On the flip side, Siemens Energy ( opens new tab rose 1% after the company said it expects to hit the upper end of its 2025 growth outlook estimates. Hiscox (HSX.L), opens new tab was the top gainer on the index, gaining 9.4% after reporting a rise in first-half insurance premiums supported by its retail business growth.
Reuters
2 hours ago
- Reuters
Charles River profit forecast clouded by order cancellations from biotechs
Aug 6 (Reuters) - Charles River Laboratories' (CRL.N), opens new tab annual profit forecast raise on Wednesday was clouded by investor concerns about the higher number of order cancellations from clients, sending the contract research firm's shares down 8% in afternoon trading. The company's quarterly book-to-bill ratio – the number of orders versus those fulfilled – came in at 0.82x. Evercore ISI analyst Elizabeth Anderson said the ratio was below Wall Street expectations of 0.94x, adding some questions remain about demand environment in the sector. Charles River CEO Jim Foster said on a conference call that while proposals were higher in the quarter, cancellations from biotechs were also higher. Contract research organizations – including Charles River, Fortrea (FTRE.O), opens new tab and ICON (ICLR.O), opens new tab – have posted better-than-expected quarterly profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing. Charles River's Foster, however, said that funding for smaller biotechs is still more cash constrained, due to the funding slowdown, and mid-sized biotechs are performing better, as many can support their R&D programs without external funding. "We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth," he added. The Wilmington, Massachusetts-based company raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, from its previous range of $9.30 to $9.80. Charles River's overall second-quarter revenue came in at $1.03 billion, surpassing analysts' estimate of $985.1 million, according to data compiled by LSEG. On an adjusted basis, quarterly profit was $3.12 per share, above estimates of $2.50.
